{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:09Z","timestamp":1792081509999,"version":"4.4.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8,23]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>We present three common variable immunodeficiency (CVID) patients with severe inflammatory bowel disease of unknown aetiology, resistant to steroid treatment, treated with infliximab. After exclusion of any infection, infliximab was given at a dose of 5\u2003mg\/kg every 4 weeks for a 3 month induction followed by every 4\u20138 weeks depending on clinical response. Two of these patients had predominantly small bowel disease; they both showed clinical response to infliximab with weight gain and improvement of quality of life scores. The third patient had large bowel involvement with profuse watery diarrhea; this patient improved dramatically within 48 hours of having infliximab treatment. All three patients have been maintained on infliximab treatment for between 5 and 53 months (mean 37 months) with no evidence of increased susceptibility to infections in the patients with small bowel disease, although the third patient developed two urinary tract infections and a herpes zoster infection following therapy. This is the first small case series to show that infliximab is a useful addition to current therapy in this rare group of patients with potentially life threatening enteritis.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2007.03481.x","type":"journal-article","created":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T10:16:04Z","timestamp":1281608164000},"page":"306-311","source":"Crossref","is-referenced-by-count":81,"title":["Anti-tumour necrosis factor-\u03b1 therapy for severe enteropathy in patients with common variable immunodeficiency (CVID)"],"prefix":"10.1093","volume":"150","author":[{"given":"I","family":"Chua","sequence":"first","affiliation":[{"name":"Department of Immunology, Royal Free Hospital Hampstead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Standish","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Royal Free Hospital Hampstead, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lear","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Free Hospital Hampstead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Harbord","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chelsea and Westminster Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Immunology, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Raeiszadeh","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Free Hospital Hampstead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Workman","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Free Hospital Hampstead"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Webster","sequence":"additional","affiliation":[{"name":"Department of Immunology, Royal Free Hospital Hampstead"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,9,5]]},"reference":[{"key":"2022010406284507200_b1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency. Clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol"},{"key":"2022010406284507200_b2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.bor.0000231906.12172.6e","article-title":"Monogenetic defects in common variable immunodeficiency: what can we learn about terminal B cell differentiation?","volume":"18","author":"Salzer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"2022010406284507200_b3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8561(05)70190-9","article-title":"Common variable immunodeficiency","volume":"21","author":"Webster","year":"2001","journal-title":"Immunol Allergy Clinics North America"},{"key":"2022010406284507200_b4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/00000478-199610000-00010","article-title":"Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia","volume":"20","author":"Washington","year":"1996","journal-title":"Am J Surg Path"},{"key":"2022010406284507200_b5","first-page":"31","article-title":"Primary hypogammaglobuliniemia: a survey of clinical manifestations and complications","volume":"86","author":"Hermaszewski","year":"1993","journal-title":"Q J Med"},{"key":"2022010406284507200_b6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/gut.35.9.1244","article-title":"Studies on the enteropathy associated with primary hypogammaglobulinemia","volume":"35","author":"Teahon","year":"1994","journal-title":"Gut"},{"key":"2022010406284507200_b7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/pgmj.75.881.161","article-title":"Primary antibody deficiency and Crohn's disease","volume":"75","author":"Conlong","year":"1999","journal-title":"Postgrad Med J"},{"key":"2022010406284507200_b8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance imfliximab for Crohn's disease: the ACCENT I trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2022010406284507200_b9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2249.2006.03209.x","article-title":"The T cell response to persistent herpes virus infections in common variable immunodeficiency","volume":"146","author":"Raesizadeh","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"2022010406284507200_b10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00054725-200405000-00011","article-title":"The pathogenicity of cytomegalovirus in inflammatory bowel disease","volume":"10","author":"Hommes","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"2022010406284507200_b11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(94)91116-9","article-title":"Cytomegalovirus reactivation and tumour necrosis factor","volume":"343","author":"Docke","year":"1994","journal-title":"Lancet"},{"key":"2022010406284507200_b12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2006.06.022","article-title":"Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with non variable immunodeficiency","volume":"131","author":"Mannon","year":"2006","journal-title":"Gastroenterology"},{"key":"2022010406284507200_b13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004836-198808000-00011","article-title":"The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study","volume":"10","author":"Boirivant","year":"1988","journal-title":"J Clin Gastroenterol"},{"key":"2022010406284507200_b14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/00001574-199907000-00006","article-title":"Medical therapy for Crohn's disease","volume":"15","author":"Hanauer","year":"1999","journal-title":"Curr Opin Gastroenterol"},{"key":"2022010406284507200_b15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022010406284507200_b16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4049\/jimmunol.164.1.488","article-title":"Up-regulation of IL-12 in monocytes: a fundamental defect in common variable immunodeficiency","volume":"164","author":"Carbronero","year":"2000","journal-title":"J Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2007.03481.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/150\/2\/306\/42037865\/j.1365-2249.2007.03481.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/150\/2\/306\/42037865\/j.1365-2249.2007.03481.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T01:38:33Z","timestamp":1641260313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/150\/2\/306\/6457670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,23]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,9,5]]},"published-print":{"date-parts":[[2007,8,23]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2007.03481.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,11]]},"published":{"date-parts":[[2007,8,23]]}}}